Original text：https://money.udn.com/money
UBI Pharma Inc. (6562.TW) announced today (6th) that its “Single-Chain Immunoglobulin Fusion Protein Technology” has received approval from the United States Patent and Trademark Office (USPTO), securing the patent (US Patent Granted US 11,820,807 B2). This groundbreaking technology extends the efficacy of pharmaceuticals, offering a substantial boost to the effectiveness of cancer treatments, whether used independently or in conjunction with existing anticancer therapies.
The fusion protein developed by UBIP combines a single-chain Fc with a biologically active molecule. This type of fusion protein effectively prolongs the serum half-life of biologically active molecules in the organism. In comparison to fusion proteins composed of two Fc regions, it better maintains the complete biological activity of biologically active molecules without functional degradation.
UB-551, one of UBIP’s products, demonstrates remarkable efficacy against Hepatitis B and C viruses, as well as significant inhibitory effects on various cancer cell types. The application of the Single-Chain Immunoglobulin Fusion Protein Technology further extends the duration of UB-551 drug efficacy, presenting a substantial enhancement in the effectiveness of cancer treatment, either as a standalone solution or in synergy with existing anticancer therapies.
UBIP proudly holds two innovative long-acting protein drug technology platforms. The “Polysaccharide Protein Fusion Technology Platform” has already secured patents in key pharmaceutical markets globally, including the United States, Europe, China, and Japan. In addition to previously obtained patents in countries such as the Republic of China, Japan, China, India, Australia, Malaysia, and Hong Kong for the “Single-Chain Immunoglobulin Fusion Protein Technology,” acquiring a patent in the United States not only fortifies the protection of this technology platform across multiple nations but also elevates its commercial value. Looking ahead, this platform is poised for expansion into international development collaborations for protein-based new drugs and the promotion and sales of derivative products in vital pharmaceutical markets.
